Let's spread the word about Immunotherapy! Click to share this page with your community.
Copy Link

Immunotherapy for Lung Cancer: PD-1 and Beyond

On November 12, 2015, Naiyer A. Rizvi, M.D., director of thoracic oncology and director of immunotherapeutics at Columbia University Medical Center, discussed current immunotherapy treatment options for patients with lung cancer, and how close we are to making these treatments available to more patients.

Dr. Rizvi is an internationally recognized leader in the treatment of lung cancer and immunotherapy drug development, and played a significant role in the FDA approval of a new class of immunotherapies, called immune checkpoint inhibitors, for melanoma and lung cancer. His research focus is studying mechanisms of sensitivity and resistance to immunotherapy. Through genetic testing of tumors, he has been able to improve the understanding of why immune checkpoint inhibitors work in certain patients. This work has been partially supported by Stand Up To Cancer-Cancer Research Institute Immunology funding. Dr. Rizvi also oversees phase I immunotherapy research and is conducting key clinical studies of novel immunotherapy drugs and immunotherapy combinations to help more patients in the fight against cancer.

This webinar is part of the Cancer Research Institute's webinar series, "Cancer Immunotherapy and You," which are offered free to the public and feature informative updates for patients and caregivers from leaders in cancer immunotherapy, followed by a Q&A. This webinar was made possible by the generous support of Bristol-Myers Squibb, along with our partners Lungevity and Free to Breathe. For more information on this webinar, or to register for upcoming webinars, please visit www.cancerresearch.org/webinars.

Top